ISRCTN98365455 https://doi.org/10.1186/ISRCTN98365455

Magnesium intervention during pregnancy

Submission date 23/08/2010	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 14/09/2010	**Overall study status** Completed	
Last Edited 05/11/2014	**Condition category** Pregnancy and Childbirth	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Ragnar Rylander

Contact details
Bjorkasvagen 21
Lerum
Sweden
443 91
+46 (0)708 40 0101
envhealth@biofact.se

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Acid-base balance and blood pressure during pregnancy: a double-blinded randomized controlled trial

Study objectives
Intervention with magnesium citrate will prevent increase in blood pressure during last part of pregnancy.
Further reading: http://www.ncbi.nlm.nih.gov/pubmed/20135136.

Ethics approval required
Old ethics approval format

Ethics approval(s)
The Gothenburg Committee, 08/03/2009, ref: 098-09

Study design
Double blind interventional randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Prevention

Participant information sheet
Not available in web format, please use contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Pregnancy

Interventions
Magnesium citrate powder (Diasporal), 12 mmol magnesium daily, taken at week 25 of pregnancy until delivery.
Control group receive no supplements. Blood pressure and proteinurea are measured routinely in all pregnancies

Intervention Type
Other

Phase
Not Applicable

Primary outcome measure
Blood pressure increase during final weeks of pregnancy

Secondary outcome measures
Symptoms of pre-eclampsia during final weeks of pregnancy

Overall study start date
01/10/2010

Completion date
01/10/2012

Eligibility

Key inclusion criteria
1. First time pregnancies
2. Urinary calcium excretion in excess of 6 mmol around pregnancy week 20

Participant type(s)
Patient

Age group
Adult

Sex
Female

Target number of participants
60

Key exclusion criteria
History of blood pressure or renal dysfunction

Date of first enrolment
01/10/2010

Date of final enrolment
01/10/2012

Locations

Countries of recruitment
Sweden

Study participating centre
Bjorkasvagen 21
Lerum
Sweden
443 91

Sponsor information

Organisation
Sodra Alvsaborgs Hospital (Sweden)

Sponsor details
Maternity care unit
Boras
Sweden
501 82
+46 (0)33 616 0000
Mats.elm@vgregion.se

Sponsor type
Hospital/treatment centre

ROR
https://ror.org/01qas6g18

Funder(s)

Funder type
Research council

Funder Name
South Alvsborg Research and Development Council (Forskning och Utveckling [FoU]) (Sweden)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2013		Yes	No